Novel anticarcinoembryonic antigen antibody–drug conjugate has antitumor activity in the existence of soluble antigen

Cancer Medicine

Volumn 6, Issue 4, 2017, Pages 798-808

  Shinmi, Daisuke ^a   Nakano, Ryosuke ^a   Mitamura, Keisuke ^a   Suzuki Imaizumi, Minami ^a   Iwano, Junko ^a   Isoda, Yuya ^a   Enokizono, Junichi ^a   Shiraishi, Yasuhisa ^a   Arakawa, Emi ^a   Tomizuka, Kazuma ^a   Masuda, Kazuhiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antibody; antibody drug conjugate; CEA; esophageal cancer; gastric cancer

Indexed keywords

15 1 32 ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; LABETUZUMAB; UNCLASSIFIED DRUG; VEDOTIN; MONOCLONAL ANTIBODY; OLIGOPEPTIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENTIATION; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MICE; OLIGOPEPTIDES; STOMACH NEOPLASMS;

EID: 85013439600     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1003     Document Type: Article

References (35)

1. Cartron, G., S. de Guibert, M. S. Dilhuydy, F. Morschhauser, V. Leblond, J. Dupuis, et al. 2014. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 124:2196–2202.
2. Gualberto, A. 2012. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin. Investig. Drugs 21:205–216.
3. Ishida, T., T. Joh, N. Uike, K. Yamamoto, A. Utsunomiya, S. Yoshida, et al. 2012. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 30:837–842.
4. Cooper, E. H., R. Turner, L. Steele, A. M. Neville, and A. M. Mackay. 1975. The contribution of serum enzymes and carcinoembryonic antigen to the early diagnosis of metastatic colorectal cancer. Br. J. Cancer 31:111–117.
5. Gold, P., and S. O. Freedman. 1965. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122:467–481.
6. Goldstein, M. J., and E. P. Mitchell. 2005. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 23:338–351.
7. Govindan, S. V., T. M. Cardillo, E. A. Rossi, P. Trisal, W. J. McBride, R. M. Sharkey, et al. 2015. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol. Pharm. 12:1836–1847.
8. Meyer, T., A. M. Gaya, G. Dancey, M. R. Stratford, S. Othman, S. K. Sharma, et al. 2009. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin. Cancer Res. 15:4484–4492.
9. Sharkey, R. M., G. Hajjar, D. Yeldell, A. Brenner, J. Burton, A. Rubin, et al. 2005. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J. Nucl. Med. 46:620–633.
10. Shibata, S., A. Raubitschek, L. Leong, M. Koczywas, L. Williams, J. Zhan, et al. 2009. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin. Cancer Res. 15:2935–2941.
11. Bramswig, K. H., M. Poettler, M. Unseld, F. Wrba, P. Uhrin, W. Zimmermann, et al. 2013. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res. 73:6584–6596.
12. Duffy, M. J., R. Lamerz, C. Haglund, A. Nicolini, M. Kalousova, L. Holubec, et al. 2014. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int. J. Cancer 134:2513–2522.
13. Locker, G. Y., S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, et al. 2006. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24:5313–5327.
14. Gerber, H. P., F. E. Koehn, and R. T. Abraham. 2013. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 30:625–639.
15. Panowksi, S., S. Bhakta, H. Raab, P. Polakis, and J. R. Junutula. 2014. Site-specific antibody drug conjugates for cancer therapy. MAbs 6:34–45.
16. Deng, C., B. Pan, and O. A. O'Connor. 2013. Brentuximab vedotin. Clin. Cancer Res. 19:22–27.
17. LoRusso, P. M., D. Weiss, E. Guardino, S. Girish, and M. X. Sliwkowski. 2011. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17:6437–6447.
18. Ashraf, S. Q., P. Umana, E. Mossner, T. Ntouroupi, P. Brunker, C. Schmidt, et al. 2009. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br. J. Cancer 101:1758–1768.
19. Conaghan, P., S. Ashraf, M. Tytherleigh, J. Wilding, E. Tchilian, D. Bicknell, et al. 2008. Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br. J. Cancer 98:1217–1225.
20. Durbin, H., S. Young, L. M. Stewart, F. Wrba, A. J. Rowan, D. Snary, et al. 1994. An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc. Natl. Acad. Sci. U S A. 91:4313–4317.
21. Stewart, L. M., S. Young, G. Watson, S. J. Mather, P. A. Bates, H. A. Band, et al. 1999. Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunol. Immunother. 47:299–306.
22. Nakamura, K., Y. Tanaka, I. Fujino, N. Hirayama, K. Shitara, and N. Hanai. 2000. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol. Immunol. 37:1035–1046.
23. Shinmi, D., E. Taguchi, J. Iwano, et al. 2016. One-step conjugation method for site-specific antibody-drug conjugates through reactive cysteine-engineered antibodies. Bioconjug Chem 27:1324–1331.
24. Austin, C. D., A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, et al. 2004. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15:5268–5282.
25. Motoki, K., E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, et al. 2005. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. 11:3126–3135.
26. Murakami, M., M. Kuroki, F. Arakawa, M. Kuwahara, S. Oikawa, H. Nakazato, et al. 1995. A reference of the GOLD classification of monoclonal antibodies against carcinoembryonic antigen to the domain structure of the carcinoembryonic antigen molecule. Hybridoma 14:19–28.
27. Hamilton, G. S. 2015. Antibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids. Biologicals 43:318–332.
28. Oberst, M. D., S. Fuhrmann, K. Mulgrew, M. Amann, L. Cheng, P. Lutterbuese, et al. 2014. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 6:1571–1584.
29. Boudousq, V., L. Bobyk, M. Busson, V. Garambois, M. Jarlier, P. Charalambatou, et al. 2013. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS ONE 8:e69613.
30. Behr, T. M., M. Behe, M. Lohr, G. Sgouros, C. Angerstein, E. Wehrmann, et al. 2000. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur. J. Nucl. Med. 27:753–765.
31. Bryan, J. N., F Jia, H. Mohsin, G. Sivaguru, W. H. Miller, C. J. Anderson, et al. 2005. Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl. Med. Biol. 32:851–858.
32. Ford, C. H., G. C. Tsaltas, P. A. Osborne, and K. Addetia. 1996. Novel flow cytometric analysis of the progress and route of internalization of a monoclonal anti-carcinoembryonic antigen (CEA) antibody. Cytometry 23:228–240.
33. Schmidt, M. M., G. M. Thurber, and K. D. Wittrup. 2008. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol. Immunother. 57:1879–1890.
34. Shih, L. B., D. M. Goldenberg, H. Xuan, H. W. Lu, M. J. Mattes, and T. C. Hall. 1994. Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol. Immunother. 38:92–98.
35. Jerjian, T. V., A. E. Glode, L. A. Thompson, and C. L. O'Bryant. 2016. Antibody-Drug Conjugates: a Clinical Pharmacy Perspective on an Emerging Cancer Therapy. Pharmacotherapy 36:99–116.